Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors

NCT01609790 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

137

Enrollment

NIH

Sponsor class

Conditions

Giant Cell Glioblastoma
Glioblastoma
Gliosarcoma
Oligodendroglioma
Recurrent Brain Neoplasm
Recurrent Glioblastoma

Interventions

BIOLOGICAL: Bevacizumab
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study
OTHER: Placebo Administration
BIOLOGICAL: Trebananib

Sponsor

National Cancer Institute (NCI)

Collaborators

[object Object]